Efficacy of a new ready-to-use vaccine against PCV-2d and Mycoplasma hyopneumoniae under experimental conditions
Mycoplasma hyopneumoniae (M. hyo) and porcine circovirus type 2 (PCV-2) are major and widespread swine pathogens, both implicated in the porcine respiratory disease complex, which can lead to significant economic losses for pig producers. PCV-2d is currently the most prevalent genotype. Vaccination...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Czech Academy of Agricultural Sciences
2025-06-01
|
| Series: | Veterinární Medicína |
| Subjects: | |
| Online Access: | https://vetmed.agriculturejournals.cz/artkey/vet-202506-0003_efficacy-of-a-new-ready-to-use-vaccine-against-pcv-2d-and-mycoplasma-hyopneumoniae-under-experimental-condition.php |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849245382326878208 |
|---|---|
| author | R Krejci P Trampus A Csagola T Szalai N Palmai A Toth N Terenyi Z Nagy NA Szeplaki G Somogyi T Barna E Rausch Z Penzes M Szaszko Z Lorincz |
| author_facet | R Krejci P Trampus A Csagola T Szalai N Palmai A Toth N Terenyi Z Nagy NA Szeplaki G Somogyi T Barna E Rausch Z Penzes M Szaszko Z Lorincz |
| author_sort | R Krejci |
| collection | DOAJ |
| description | Mycoplasma hyopneumoniae (M. hyo) and porcine circovirus type 2 (PCV-2) are major and widespread swine pathogens, both implicated in the porcine respiratory disease complex, which can lead to significant economic losses for pig producers. PCV-2d is currently the most prevalent genotype. Vaccination against these two pathogens helps mitigate their impact on pig health and performance. The use of ready-to-mix or ready-to-use (RTU) vaccines targeting PCV-2a or PCV-2a/b and M. hyo is a common practice. This study aimed to evaluate the efficacy of a novel RTU vaccine containing PCV-2d and M. hyo antigens under experimental conditions. Several challenge trials were conducted using PCV-2a, PCV-2b, PCV-2d, and M. hyo to assess the level of protection conferred against different PCV-2 genotypes and M. hyo, as well as to determine the duration of protection. This study demonstrated that the bivalent PCV-2/M. hyo vaccine induces both early and long-lasting protection against infections caused by M. hyo and PCV-2. In addition, cross-protection against the three major PCV-2 genotypes was confirmed. |
| format | Article |
| id | doaj-art-b4bfb69a41f84e888c1895130f30a5e4 |
| institution | Kabale University |
| issn | 0375-8427 1805-9392 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Czech Academy of Agricultural Sciences |
| record_format | Article |
| series | Veterinární Medicína |
| spelling | doaj-art-b4bfb69a41f84e888c1895130f30a5e42025-08-20T03:58:49ZengCzech Academy of Agricultural SciencesVeterinární Medicína0375-84271805-93922025-06-0170619620210.17221/6/2025-VETMEDvet-202506-0003Efficacy of a new ready-to-use vaccine against PCV-2d and Mycoplasma hyopneumoniae under experimental conditionsR Krejci0P Trampus1A Csagola2T Szalai3N Palmai4A Toth5N Terenyi6Z Nagy7NA Szeplaki8G Somogyi9T Barna10E Rausch11Z Penzes12M Szaszko13Z Lorincz14Ceva Sante Animale, Libourne Cedex, FranceCeva-Phylaxia Zrt., Budapest, HungaryCeva-Phylaxia Zrt., Budapest, HungaryCeva-Phylaxia Zrt., Budapest, HungaryCeva-Phylaxia Zrt., Budapest, HungaryCeva-Phylaxia Zrt., Budapest, HungaryCeva-Phylaxia Zrt., Budapest, HungaryCeva-Phylaxia Zrt., Budapest, HungaryCeva-Phylaxia Zrt., Budapest, HungaryCeva-Phylaxia Zrt., Budapest, HungaryCeva-Phylaxia Zrt., Budapest, HungaryCeva-Phylaxia Zrt., Budapest, HungaryCeva-Phylaxia Zrt., Budapest, HungaryTargetEx Biosciences Ltd., Dunakeszi, HungaryTargetEx Biosciences Ltd., Dunakeszi, HungaryMycoplasma hyopneumoniae (M. hyo) and porcine circovirus type 2 (PCV-2) are major and widespread swine pathogens, both implicated in the porcine respiratory disease complex, which can lead to significant economic losses for pig producers. PCV-2d is currently the most prevalent genotype. Vaccination against these two pathogens helps mitigate their impact on pig health and performance. The use of ready-to-mix or ready-to-use (RTU) vaccines targeting PCV-2a or PCV-2a/b and M. hyo is a common practice. This study aimed to evaluate the efficacy of a novel RTU vaccine containing PCV-2d and M. hyo antigens under experimental conditions. Several challenge trials were conducted using PCV-2a, PCV-2b, PCV-2d, and M. hyo to assess the level of protection conferred against different PCV-2 genotypes and M. hyo, as well as to determine the duration of protection. This study demonstrated that the bivalent PCV-2/M. hyo vaccine induces both early and long-lasting protection against infections caused by M. hyo and PCV-2. In addition, cross-protection against the three major PCV-2 genotypes was confirmed.https://vetmed.agriculturejournals.cz/artkey/vet-202506-0003_efficacy-of-a-new-ready-to-use-vaccine-against-pcv-2d-and-mycoplasma-hyopneumoniae-under-experimental-condition.phpenzootic pneumoniapcv-2 diseasevaccination |
| spellingShingle | R Krejci P Trampus A Csagola T Szalai N Palmai A Toth N Terenyi Z Nagy NA Szeplaki G Somogyi T Barna E Rausch Z Penzes M Szaszko Z Lorincz Efficacy of a new ready-to-use vaccine against PCV-2d and Mycoplasma hyopneumoniae under experimental conditions Veterinární Medicína enzootic pneumonia pcv-2 disease vaccination |
| title | Efficacy of a new ready-to-use vaccine against PCV-2d and Mycoplasma hyopneumoniae under experimental conditions |
| title_full | Efficacy of a new ready-to-use vaccine against PCV-2d and Mycoplasma hyopneumoniae under experimental conditions |
| title_fullStr | Efficacy of a new ready-to-use vaccine against PCV-2d and Mycoplasma hyopneumoniae under experimental conditions |
| title_full_unstemmed | Efficacy of a new ready-to-use vaccine against PCV-2d and Mycoplasma hyopneumoniae under experimental conditions |
| title_short | Efficacy of a new ready-to-use vaccine against PCV-2d and Mycoplasma hyopneumoniae under experimental conditions |
| title_sort | efficacy of a new ready to use vaccine against pcv 2d and mycoplasma hyopneumoniae under experimental conditions |
| topic | enzootic pneumonia pcv-2 disease vaccination |
| url | https://vetmed.agriculturejournals.cz/artkey/vet-202506-0003_efficacy-of-a-new-ready-to-use-vaccine-against-pcv-2d-and-mycoplasma-hyopneumoniae-under-experimental-condition.php |
| work_keys_str_mv | AT rkrejci efficacyofanewreadytousevaccineagainstpcv2dandmycoplasmahyopneumoniaeunderexperimentalconditions AT ptrampus efficacyofanewreadytousevaccineagainstpcv2dandmycoplasmahyopneumoniaeunderexperimentalconditions AT acsagola efficacyofanewreadytousevaccineagainstpcv2dandmycoplasmahyopneumoniaeunderexperimentalconditions AT tszalai efficacyofanewreadytousevaccineagainstpcv2dandmycoplasmahyopneumoniaeunderexperimentalconditions AT npalmai efficacyofanewreadytousevaccineagainstpcv2dandmycoplasmahyopneumoniaeunderexperimentalconditions AT atoth efficacyofanewreadytousevaccineagainstpcv2dandmycoplasmahyopneumoniaeunderexperimentalconditions AT nterenyi efficacyofanewreadytousevaccineagainstpcv2dandmycoplasmahyopneumoniaeunderexperimentalconditions AT znagy efficacyofanewreadytousevaccineagainstpcv2dandmycoplasmahyopneumoniaeunderexperimentalconditions AT naszeplaki efficacyofanewreadytousevaccineagainstpcv2dandmycoplasmahyopneumoniaeunderexperimentalconditions AT gsomogyi efficacyofanewreadytousevaccineagainstpcv2dandmycoplasmahyopneumoniaeunderexperimentalconditions AT tbarna efficacyofanewreadytousevaccineagainstpcv2dandmycoplasmahyopneumoniaeunderexperimentalconditions AT erausch efficacyofanewreadytousevaccineagainstpcv2dandmycoplasmahyopneumoniaeunderexperimentalconditions AT zpenzes efficacyofanewreadytousevaccineagainstpcv2dandmycoplasmahyopneumoniaeunderexperimentalconditions AT mszaszko efficacyofanewreadytousevaccineagainstpcv2dandmycoplasmahyopneumoniaeunderexperimentalconditions AT zlorincz efficacyofanewreadytousevaccineagainstpcv2dandmycoplasmahyopneumoniaeunderexperimentalconditions |